Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.

Launched by UNIVERSITEIT ANTWERPEN · Aug 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying chronic pain that some women experience after treatment for breast cancer. Research shows that up to 40% of these women can suffer from ongoing pain, which can significantly affect their daily lives. The goal of the study is to identify specific markers, called biomarkers, that can help predict, assess, and diagnose chronic pain after breast cancer treatment. By looking at different factors, including brain imaging, pain sensitivity, and psychological aspects, the researchers hope to better understand how pain develops over time in breast cancer survivors.

To participate in this trial, women must be diagnosed with unilateral (one-sided) breast cancer and have experienced mild pain (rated less than 3 out of 10) in the week before joining. They should be receiving their first cancer diagnosis and have no major pre-existing pain or neurological disorders. Participants will be monitored for changes in their pain and related factors from the time of their diagnosis until one year after their surgery. This study is important because it aims to improve how chronic pain is recognized and treated in breast cancer survivors, ultimately leading to better quality of life for these women.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Unilateral breast cancer
• • Pain at enrollment \<3/10 on average during the past week
• • First cancer diagnosis
• Exclusion Criteria:
• • Pre-existing pain conditions
• • major pre-existing neurological disorders
• • No recurrent cancer or metastasis
• • No previous surgery in area